Prolactin synthesis by lymphocytes from patients with systemic sclerosis

被引:24
作者
Czuwara-Ladykowska, Joanna
Sicinska, Justyna
Olszewska, Malgorzata
Uhrynowska-Tyszkiewicz, Izabela
Rudnicka, Lidia
机构
[1] CSK MSWiA, Dept Dermatol, PL-02507 Warsaw, Poland
[2] Warsaw Acad Med & Hosp, Dept Dermatol, PL-02008 Warsaw, Poland
[3] Polish Acad Sci, PL-00901 Warsaw, Poland
关键词
scleroderma; T cells; interleukin; 2;
D O I
10.1016/j.biopha.2006.02.007
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 [基础医学];
摘要
Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of the skin and internal organs. It has been demonstrated that serum prolactin levels are increased in patients with various connective tissue diseases. The aim of this study was to investigate the possible source of excessive prolactin synthesis in SSc and its effects on immune cells. The study group consisted of 52 patients with diffuse SSc (44 women and eight men) and 52 age and sex matched healthy controls. The methods used were: ELISA and indirect immunofluorescence. Our results show significantly elevated level of prolactin in male and female patients with SSc and increased prolactin production by SSc lymphocytes as compared to healthy donors X lymphocytes (25.4 +/- 11.0 vs. 13.4 +/- 5.0 absorbance units). Patients X and healthy controls X lymphocytes, showed equal presence of prolactin receptors. Soluble interleukin 2 receptor (CD25) concentration, was significantly higher in supernatants of prolactin stimulated lymphocytes, as compared to non-stimulated lymphocytes. We conclude that lymphocytes might contribute to elevated prolactin levels in patients with SSc and that these cells themselves may be sensitive to prolactin stimulation. Therefore, a pharmacologic attempt to lower prolactin levels in patients with SSc could proof beneficial. (c) 2006 Elsevier SAS. All rights reserved.
引用
收藏
页码:152 / 155
页数:4
相关论文
共 13 条
[1]
PRELIMINARY CRITERIA FOR THE CLASSIFICATION OF SYSTEMIC-SCLEROSIS (SCLERODERMA) [J].
不详 .
ARTHRITIS AND RHEUMATISM, 1980, 23 (05) :581-590
[2]
Generini S, 1999, ADV EXP MED BIOL, V455, P73
[3]
High serum level of prolactin in patients with systemic sclerosis [J].
Kucharz, EJ ;
Jarczyk, R ;
Jonderko, G ;
RubiszBrzezinska, J ;
BrzezinskaWcislo, L .
CLINICAL RHEUMATOLOGY, 1996, 15 (03) :314-314
[4]
La Montagna G, 2004, CLIN EXP RHEUMATOL, V22, P145
[5]
Assessment of pituitary gonadotropin release to gonadotropin releasing hormone/thyroid-stimulating hormone stimulation in women with systemic sclerosis [J].
La Montagna, G ;
Baruffo, A ;
Pasquali, D ;
Bellastella, A ;
Tirri, G ;
Sinisi, AA .
RHEUMATOLOGY, 2001, 40 (03) :310-314
[6]
Lis A, 2001, Pol Merkur Lekarski, V11, P206
[7]
Bromocriptine in rheumatic and autoimmune diseases [J].
McMurray, RW .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2001, 31 (01) :21-32
[8]
Prolactin as a modulator of B cell function: Implications for SLE [J].
Peeva, E ;
Venkatesh, J ;
Michael, D ;
Diamond, B .
BIOMEDICINE & PHARMACOTHERAPY, 2004, 58 (05) :310-319
[9]
ADHESION OF PERIPHERAL-BLOOD MONONUCLEAR-CELLS TO VASCULAR ENDOTHELIUM IN PATIENTS WITH SYSTEMIC-SCLEROSIS (SCLERODERMA) [J].
RUDNICKA, L ;
MAJEWSKI, S ;
BLASZCZYK, M ;
SKIENDZIELEWSKA, A ;
MAKIELA, B ;
SKOPINSKA, M ;
JABLONSKA, S .
ARTHRITIS AND RHEUMATISM, 1992, 35 (07) :771-775
[10]
Shahin AA, 2002, Z RHEUMATOL, V61, P703, DOI 10.1007/s00393-002-0413-7